Targeting ACSS2/AATF‐sFasL Axis Abrogates CD8+ T Cell Apoptosis and Restores Anti‐Tumor Immunity in PNET Patient‐Derived Models. The gene discussed is FASLG; the disease is primitive neuroectodermal tumor.